Figure 2.

VN and DCD serum levels in early‐stage melanoma patients. (a) VN serum levels in stage I–II patients. Patients were divided according to tumor progression as disease‐free patients (more than 10 years disease‐free) and metastatic (patients who developed metastasis during the follow‐up). (b) Disease‐free survival curves for melanoma patients relative to their serum VN levels. Stage I–II patients were divided into two groups according to the mean + 2 SD of the VN level in the control group (23.5 µg/ml). (c) DCD serum levels in stage I–II patients. Patients were divided as described above. (d) Decision‐tree algorithm classified stage II patients relative to their DCD serum levels. A low DCD concentration (<2.98 μg/ml) has an 80% accuracy in predicting metastasis for stage II melanoma patients.